25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Akebia Therapeutics Inc
Buy, Hold or Sell?

Let's analyze Akebia Therapeutics Inc together

I guess you are interested in Akebia Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Akebia Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Akebia Therapeutics Inc

I send you an email if I find something interesting about Akebia Therapeutics Inc.

1. Quick Overview

1.1. Quick analysis of Akebia Therapeutics Inc (30 sec.)










1.2. What can you expect buying and holding a share of Akebia Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
€-0.22
Expected worth in 1 year
€-0.25
How sure are you?
30.8%

+ What do you gain per year?

Total Gains per Share
€-0.03
Return On Investment
-1.5%

For what price can you sell your share?

Current Price per Share
€1.77
Expected price per share
€1.382 - €3
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Akebia Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)
€1.77
Intrinsic Value Per Share
€10.04 - €12.24
Total Value Per Share
€9.82 - €12.02

2.2. Growth of Akebia Therapeutics Inc (5 min.)




Is Akebia Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?-$50.4m-$18.8m-$16.6m-46.9%

How much money is Akebia Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$12.4m-$16.3m$3.8m30.7%
Net Profit Margin-31.8%-33.8%--

How much money comes from the company's main activities?

2.3. Financial Health of Akebia Therapeutics Inc (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Akebia Therapeutics Inc?

Welcome investor! Akebia Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Akebia Therapeutics Inc.

First you should know what it really means to hold a share of Akebia Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Akebia Therapeutics Inc is €1.766. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Akebia Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Akebia Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €-0.22. Based on the TTM, the Book Value Change Per Share is €-0.01 per quarter. Based on the YOY, the Book Value Change Per Share is €-0.07 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Akebia Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps-0.10-5.8%-0.06-3.4%-0.09-4.9%-0.15-8.2%-0.15-8.2%
Usd Book Value Change Per Share-0.08-4.4%-0.01-0.4%-0.07-4.0%-0.02-1.0%-0.02-1.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.08-4.4%-0.01-0.4%-0.07-4.0%-0.02-1.0%-0.02-1.0%
Usd Price Per Share1.26-1.33-0.77-1.13-1.13-
Price to Earnings Ratio-3.06-19.45--2.64-4.92-4.92-
Price-to-Total Gains Ratio-16.27-10.54--11.63--0.70--0.70-
Price to Book Ratio-5.29--8.38--0.30--1.19--1.19-
Price-to-Total Gains Ratio-16.27-10.54--11.63--0.70--0.70-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.916993
Number of shares521
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.01-0.02
Usd Total Gains Per Share-0.01-0.02
Gains per Quarter (521 shares)-3.77-9.55
Gains per Year (521 shares)-15.07-38.19
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-15-250-38-48
20-30-400-76-86
30-45-550-115-124
40-60-700-153-162
50-75-850-191-200
60-90-1000-229-238
70-105-1150-267-276
80-121-1300-306-314
90-136-1450-344-352
100-151-1600-382-390

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%2.010.00.016.7%2.011.00.015.4%2.011.00.015.4%2.011.00.015.4%
Book Value Change Per Share2.02.00.050.0%3.09.00.025.0%4.09.00.030.8%4.09.00.030.8%4.09.00.030.8%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.013.00.0%0.00.013.00.0%0.00.013.00.0%
Total Gains per Share2.02.00.050.0%3.09.00.025.0%4.09.00.030.8%4.09.00.030.8%4.09.00.030.8%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Akebia Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.071-0.007-91%-0.066-8%-0.017-76%-0.017-76%
Book Value Per Share---0.219-0.158-28%-0.092-58%0.049-551%0.049-551%
Current Ratio--1.5241.363+12%1.386+10%1.351+13%1.351+13%
Debt To Asset Ratio--1.2431.161+7%1.078+15%1.029+21%1.029+21%
Debt To Equity Ratio----0%16.770-100%10.283-100%10.283-100%
Dividend Per Share----0%-0%-0%-0%
Enterprise Value--8350870.84215292378.683-45%-143162661.530+1814%-124156904.036+1587%-124156904.036+1587%
Eps---0.095-0.055-42%-0.080-15%-0.134+42%-0.134+42%
Ev To Ebitda Ratio--infnannan%infnan%nannan%nannan%
Ev To Sales Ratio--0.0560.155-64%-0.742+1430%-0.494+985%-0.494+985%
Free Cash Flow Per Share---0.029-0.042+46%-0.094+224%-0.097+234%-0.097+234%
Free Cash Flow To Equity Per Share---0.024-0.014-41%-0.124+420%-0.083+249%-0.083+249%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--12.244--------
Intrinsic Value_10Y_min--10.044--------
Intrinsic Value_1Y_max---0.099--------
Intrinsic Value_1Y_min---0.098--------
Intrinsic Value_3Y_max--0.714--------
Intrinsic Value_3Y_min--0.661--------
Intrinsic Value_5Y_max--2.745--------
Intrinsic Value_5Y_min--2.461--------
Market Cap--245600403.642254002013.483-3%132500220.370+85%197447125.349+24%197447125.349+24%
Net Profit Margin---0.535-0.318-41%-0.338-37%-0.529-1%-0.529-1%
Operating Margin----0%-0%-0%-0%
Operating Ratio--1.7121.606+7%1.595+7%1.861-8%1.861-8%
Pb Ratio-8.046-52%-5.290-8.376+58%-0.297-94%-1.194-77%-1.194-77%
Pe Ratio-4.661-52%-3.06419.452-116%-2.639-14%4.920-162%4.920-162%
Price Per Share1.766+34%1.1611.230-6%0.708+64%1.039+12%1.039+12%
Price To Free Cash Flow Ratio-15.139-52%-9.953-11.624+17%0.614-1722%-3.782-62%-3.782-62%
Price To Total Gains Ratio-24.745-52%-16.26810.541-254%-11.631-29%-0.699-96%-0.699-96%
Quick Ratio--0.4900.390+25%0.255+92%0.290+69%0.290+69%
Return On Assets---0.105-0.058-45%-0.061-42%-0.071-32%-0.071-32%
Return On Equity----0%-0.3920%-0.7070%-0.7070%
Total Gains Per Share---0.071-0.007-91%-0.066-8%-0.017-76%-0.017-76%
Usd Book Value---50400114.965-35498172.319-30%-18837045.468-63%7578639.625-765%7578639.625-765%
Usd Book Value Change Per Share---0.077-0.007-91%-0.071-8%-0.018-76%-0.018-76%
Usd Book Value Per Share---0.238-0.172-28%-0.100-58%0.053-551%0.053-551%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Enterprise Value--9064870.29916599877.060-45%-155403069.090+1814%-134772319.331+1587%-134772319.331+1587%
Usd Eps---0.103-0.059-42%-0.087-15%-0.146+42%-0.146+42%
Usd Free Cash Flow---6696749.532-9632639.726+44%-18938041.691+183%-19380352.071+189%-19380352.071+189%
Usd Free Cash Flow Per Share---0.032-0.046+46%-0.103+224%-0.106+234%-0.106+234%
Usd Free Cash Flow To Equity Per Share---0.026-0.015-41%-0.135+420%-0.090+249%-0.090+249%
Usd Market Cap--266599238.153275719185.636-3%143828989.212+85%214328854.566+24%214328854.566+24%
Usd Price Per Share1.917+34%1.2601.335-6%0.769+64%1.128+12%1.128+12%
Usd Profit---21752334.500-12481079.000-43%-16306652.375-25%-26829635.500+23%-26829635.500+23%
Usd Revenue--40628094.00046100913.625-12%52540099.625-23%59223961.500-31%59223961.500-31%
Usd Total Gains Per Share---0.077-0.007-91%-0.071-8%-0.018-76%-0.018-76%
 EOD+4 -2MRQTTM+7 -26YOY+17 -175Y+21 -1310Y+21 -13

3.3 Fundamental Score

Let's check the fundamental score of Akebia Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-4.661
Price to Book Ratio (EOD)Between0-1-8.046
Net Profit Margin (MRQ)Greater than0-0.535
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.490
Current Ratio (MRQ)Greater than11.524
Debt to Asset Ratio (MRQ)Less than11.243
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.105
Total2/10 (20.0%)

3.4 Technical Score

Let's check the technical score of Akebia Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5044.503
Ma 20Greater thanMa 501.779
Ma 50Greater thanMa 1001.911
Ma 100Greater thanMa 2001.814
OpenGreater thanClose1.766
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About Akebia Therapeutics Inc

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its debts by selling its assets.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is fair priced.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Akebia Therapeutics Inc earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare Akebia Therapeutics Inc to the  industry mean.
  • A Net Profit Margin of -53.5% means that €-0.54 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Akebia Therapeutics Inc:

  • The MRQ is -53.5%. The company is making a huge loss. -2
  • The TTM is -31.8%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-53.5%TTM-31.8%-21.7%
TTM-31.8%YOY-33.8%+2.0%
TTM-31.8%5Y-52.9%+21.0%
5Y-52.9%10Y-52.9%0.0%
4.3.1.2. Return on Assets

Shows how efficient Akebia Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Akebia Therapeutics Inc to the  industry mean.
  • -10.5% Return on Assets means that Akebia Therapeutics Inc generated €-0.11 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Akebia Therapeutics Inc:

  • The MRQ is -10.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -5.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-10.5%TTM-5.8%-4.7%
TTM-5.8%YOY-6.1%+0.3%
TTM-5.8%5Y-7.1%+1.3%
5Y-7.1%10Y-7.1%0.0%
4.3.1.3. Return on Equity

Shows how efficient Akebia Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Akebia Therapeutics Inc to the  industry mean.
  • 0.0% Return on Equity means Akebia Therapeutics Inc generated €0.00 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Akebia Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-39.2%+39.2%
TTM-5Y-70.7%+70.7%
5Y-70.7%10Y-70.7%0.0%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Akebia Therapeutics Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Akebia Therapeutics Inc is operating .

  • Measures how much profit Akebia Therapeutics Inc makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Akebia Therapeutics Inc to the  industry mean.
  • An Operating Margin of 0.0% means the company generated €0.00  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Akebia Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
4.3.2.2. Operating Ratio

Measures how efficient Akebia Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to  industry mean).
  • An Operation Ratio of 1.71 means that the operating costs are €1.71 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Akebia Therapeutics Inc:

  • The MRQ is 1.712. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.606. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.712TTM1.606+0.107
TTM1.606YOY1.595+0.010
TTM1.6065Y1.861-0.255
5Y1.86110Y1.8610.000
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Akebia Therapeutics Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Akebia Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to  industry mean).
  • A Current Ratio of 1.52 means the company has €1.52 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Akebia Therapeutics Inc:

  • The MRQ is 1.524. The company is able to pay all its short-term debts. +1
  • The TTM is 1.363. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.524TTM1.363+0.161
TTM1.363YOY1.386-0.024
TTM1.3635Y1.351+0.012
5Y1.35110Y1.3510.000
4.4.3.2. Quick Ratio

Measures if Akebia Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Akebia Therapeutics Inc to the  industry mean.
  • A Quick Ratio of 0.49 means the company can pay off €0.49 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Akebia Therapeutics Inc:

  • The MRQ is 0.490. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.390. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.490TTM0.390+0.099
TTM0.390YOY0.255+0.135
TTM0.3905Y0.290+0.100
5Y0.29010Y0.2900.000
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Akebia Therapeutics Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Akebia Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Akebia Therapeutics Inc to industry mean.
  • A Debt to Asset Ratio of 1.24 means that Akebia Therapeutics Inc assets are financed with 124.3% credit (debt) and the remaining percentage (100% - 124.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Akebia Therapeutics Inc:

  • The MRQ is 1.243. The company is just not able to pay all its debts by selling its assets. -1
  • The TTM is 1.161. The company is just not able to pay all its debts by selling its assets. -1
Trends
Current periodCompared to+/- 
MRQ1.243TTM1.161+0.082
TTM1.161YOY1.078+0.083
TTM1.1615Y1.029+0.132
5Y1.02910Y1.0290.000
4.5.4.2. Debt to Equity Ratio

Measures if Akebia Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Akebia Therapeutics Inc to the  industry mean.
  • A Debt to Equity ratio of 0.0% means that company has €0.00 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Akebia Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY16.770-16.770
TTM-5Y10.283-10.283
5Y10.28310Y10.2830.000
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings Akebia Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Akebia Therapeutics Inc to the  industry mean.
  • A PE ratio of -3.06 means the investor is paying €-3.06 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Akebia Therapeutics Inc:

  • The EOD is -4.661. Based on the earnings, the company is expensive. -2
  • The MRQ is -3.064. Based on the earnings, the company is expensive. -2
  • The TTM is 19.452. Based on the earnings, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD-4.661MRQ-3.064-1.597
MRQ-3.064TTM19.452-22.516
TTM19.452YOY-2.639+22.091
TTM19.4525Y4.920+14.532
5Y4.92010Y4.9200.000
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Akebia Therapeutics Inc:

  • The EOD is -15.139. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -9.953. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -11.624. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-15.139MRQ-9.953-5.186
MRQ-9.953TTM-11.624+1.671
TTM-11.624YOY0.614-12.238
TTM-11.6245Y-3.782-7.842
5Y-3.78210Y-3.7820.000
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Akebia Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to industry mean).
  • A PB ratio of -5.29 means the investor is paying €-5.29 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Akebia Therapeutics Inc:

  • The EOD is -8.046. Based on the equity, the company is expensive. -2
  • The MRQ is -5.290. Based on the equity, the company is expensive. -2
  • The TTM is -8.376. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-8.046MRQ-5.290-2.756
MRQ-5.290TTM-8.376+3.087
TTM-8.376YOY-0.297-8.079
TTM-8.3765Y-1.194-7.182
5Y-1.19410Y-1.1940.000
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2023-09-302023-12-312024-03-312024-06-302024-09-30
Net Invested Capital  2,9408363,776-1,1162,6601,2803,940-15,038-11,098



6.2. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets207,142
Total Liabilities257,544
Total Stockholder Equity-50,402
 As reported
Total Liabilities 257,544
Total Stockholder Equity+ -50,402
Total Assets = 207,142

Assets

Total Assets207,142
Total Current Assets100,120
Long-term Assets107,022
Total Current Assets
Cash And Cash Equivalents 34,019
Net Receivables 32,170
Inventory 20,493
Other Current Assets 6,211
Total Current Assets  (as reported)100,120
Total Current Assets  (calculated)92,893
+/- 7,227
Long-term Assets
Property Plant Equipment 11,833
Goodwill 59,044
Intangible Assets 9,011
Long-term Assets Other 27,134
Long-term Assets  (as reported)107,022
Long-term Assets  (calculated)107,022
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities65,709
Long-term Liabilities191,835
Total Stockholder Equity-50,402
Total Current Liabilities
Accounts payable 13,494
Other Current Liabilities 2,957
Total Current Liabilities  (as reported)65,709
Total Current Liabilities  (calculated)16,451
+/- 49,258
Long-term Liabilities
Long term Debt 38,355
Capital Lease Obligations Min Short Term Debt10,226
Long-term Liabilities Other 104,839
Long-term Liabilities  (as reported)191,835
Long-term Liabilities  (calculated)153,420
+/- 38,415
Total Stockholder Equity
Total Stockholder Equity (as reported)-50,402
Total Stockholder Equity (calculated)0
+/- 50,402
Other
Capital Stock2
Common Stock Shares Outstanding 211,542
Net Debt 4,336
Net Invested Capital -12,047
Net Working Capital 34,411
Property Plant and Equipment Gross 11,833



6.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-30
> Total Assets 
602,267
525,550
535,356
521,804
435,894
356,054
276,858
253,712
234,998
241,703
225,477
220,196
207,142
207,142220,196225,477241,703234,998253,712276,858356,054435,894521,804535,356525,550602,267
   > Total Current Assets 
330,084
272,010
302,687
304,163
237,512
185,182
120,719
118,447
109,602
118,149
112,944
112,097
100,120
100,120112,097112,944118,149109,602118,447120,719185,182237,512304,163302,687272,010330,084
       Cash And Cash Equivalents 
207,204
149,800
174,562
143,893
144,761
90,466
56,953
53,572
46,529
42,925
41,961
39,499
34,019
34,01939,49941,96142,92546,52953,57256,95390,466144,761143,893174,562149,800207,204
       Net Receivables 
49,690
50,875
64,582
81,869
23,094
40,284
17,781
19,572
22,592
39,290
26,620
29,765
32,170
32,17029,76526,62039,29022,59219,57217,78140,28423,09481,86964,58250,87549,690
       Inventory 
33,688
38,195
39,422
36,272
40,039
21,568
20,604
20,905
18,442
15,691
25,532
23,872
20,493
20,49323,87225,53215,69118,44220,90520,60421,56840,03936,27239,42238,19533,688
   > Long-term Assets 
272,183
253,540
232,669
217,641
198,382
170,872
156,139
135,265
125,396
123,554
112,533
108,099
107,022
107,022108,099112,533123,554125,396135,265156,139170,872198,382217,641232,669253,540272,183
       Property Plant Equipment 
0
0
0
0
35,959
34,372
32,774
18,810
17,437
16,045
14,664
13,255
11,833
11,83313,25514,66416,04517,43718,81032,77434,37235,9590000
       Goodwill 
55,053
55,053
55,053
55,053
55,053
59,044
55,053
59,044
59,044
59,044
59,044
59,044
59,044
59,04459,04459,04459,04459,04459,04455,05359,04455,05355,05355,05355,05355,053
       Intangible Assets 
117,138
108,127
99,116
90,106
81,095
72,084
63,074
54,063
45,053
36,042
27,032
18,021
9,011
9,01118,02127,03236,04245,05354,06363,07472,08481,09590,10699,116108,127117,138
       Long-term Assets Other 
69,604
49,754
39,418
34,953
26,275
5,372
5,238
3,348
3,862
12,423
11,793
17,779
27,134
27,13417,77911,79312,4233,8623,3485,2385,37226,27534,95339,41849,75469,604
> Total Liabilities 
465,117
449,094
509,240
459,504
422,041
350,824
291,210
280,519
274,420
272,287
252,735
253,950
257,544
257,544253,950252,735272,287274,420280,519291,210350,824422,041459,504509,240449,094465,117
   > Total Current Liabilities 
189,205
256,493
253,914
233,680
187,965
129,536
82,944
92,184
79,702
99,870
66,487
107,300
65,709
65,709107,30066,48799,87079,70292,18482,944129,536187,965233,680253,914256,493189,205
       Short Long Term Debt 
0
97,543
97,848
98,158
65,947
32,000
24,000
24,000
8,000
17,500
0
0
0
00017,5008,00024,00024,00032,00065,94798,15897,84897,5430
       Accounts payable 
28,809
33,588
19,466
24,944
19,708
18,021
12,577
11,776
9,038
14,635
11,882
10,107
13,494
13,49410,10711,88214,6359,03811,77612,57718,02119,70824,94419,46633,58828,809
       Other Current Liabilities 
0
0
16,500
14,247
13,681
6,576
0
4,476
5,644
4,602
4,812
4,411
2,957
2,9574,4114,8124,6025,6444,47606,57613,68114,24716,50000
   > Long-term Liabilities 
275,912
192,601
255,326
225,824
234,076
221,288
208,266
188,335
194,718
172,417
186,248
146,650
191,835
191,835146,650186,248172,417194,718188,335208,266221,288234,076225,824255,326192,601275,912
       Long term Debt 
97,230
0
0
0
0
34,078
26,296
18,486
34,613
17,183
30,145
38,031
38,355
38,35538,03130,14517,18334,61318,48626,29634,078000097,230
       Capital Lease Obligations Min Short Term Debt
25,980
38,505
37,344
36,155
34,943
33,705
32,578
16,237
15,088
13,438
12,707
11,478
10,226
10,22611,47812,70713,43815,08816,23732,57833,70534,94336,15537,34438,50525,980
       Long-term Liabilities Other 
128,530
135,604
156,279
149,685
159,337
73,201
69,702
73,690
65,476
62,898
60,269
59,658
104,839
104,83959,65860,26962,89865,47673,69069,70273,201159,337149,685156,279135,604128,530
> Total Stockholder Equity
137,150
76,456
26,116
62,300
13,853
5,230
-14,352
-26,807
-39,422
-30,584
-27,258
-33,754
-50,402
-50,402-33,754-27,258-30,584-39,422-26,807-14,3525,23013,85362,30026,11676,456137,150
   Common Stock0000000000000
   Retained Earnings Total Equity0000000000000
   Accumulated Other Comprehensive Income 0000000000000
   Capital Surplus 0000000000000
   Treasury Stock0000000000000
   Other Stockholders Equity 0000000000000



6.4. Balance Sheets

Currency in USD. All numbers in thousands.




6.5. Cash Flows

Currency in USD. All numbers in thousands.




6.6. Income Statements

Currency in EUR. All numbers in thousands.


6.7. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue194,623
Cost of Revenue-74,149
Gross Profit120,474120,474
 
Operating Income (+$)
Gross Profit120,474
Operating Expense-240,698
Operating Income-46,075-120,224
 
Operating Expense (+$)
Research Development63,079
Selling General Administrative100,233
Selling And Marketing Expenses-
Operating Expense240,698163,312
 
Net Interest Income (+$)
Interest Income-
Interest Expense-6,032
Other Finance Cost-0
Net Interest Income-6,032
 
Pretax Income (+$)
Operating Income-46,075
Net Interest Income-6,032
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-51,925-46,257
EBIT - interestExpense = -6,032
-51,925
-45,893
Interest Expense6,032
Earnings Before Interest and Taxes (EBIT)--45,893
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-51,925
Tax Provision--
Net Income From Continuing Ops-51,925-51,925
Net Income-51,925
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net1826,032
 

Technical Analysis of Akebia Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Akebia Therapeutics Inc. The general trend of Akebia Therapeutics Inc is NEUTRAL with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Akebia Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (0.0%) Bearish trend (0.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Akebia Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 2.28 < 3.

The bearish price targets are: 1.473 > 1.389 > 1.382.

Tweet this
Akebia Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Akebia Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 7/14.
The longshort score for the Moving Averages is 0/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Akebia Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Akebia Therapeutics Inc. The current macd is -0.0547579.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Akebia Therapeutics Inc price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Akebia Therapeutics Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Akebia Therapeutics Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Akebia Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartAkebia Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Akebia Therapeutics Inc. The current adx is 22.91.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Akebia Therapeutics Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Akebia Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Akebia Therapeutics Inc. The current sar is 1.627.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Akebia Therapeutics Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Akebia Therapeutics Inc. The current rsi is 44.50. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Akebia Therapeutics Inc Daily Relative Strength Index (RSI) ChartAkebia Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Akebia Therapeutics Inc. The current phase is Overbought in neutral market.

The long score for the Stochastic Oscillator is 5/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Akebia Therapeutics Inc price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
Akebia Therapeutics Inc Daily Stochastic Oscillator ChartAkebia Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Akebia Therapeutics Inc. The current cci is -8.05121098.

Akebia Therapeutics Inc Daily Commodity Channel Index (CCI) ChartAkebia Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Akebia Therapeutics Inc. The current cmo is -5.09126912.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Akebia Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartAkebia Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Akebia Therapeutics Inc. The current willr is -11.46496815.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Akebia Therapeutics Inc Daily Williams %R ChartAkebia Therapeutics Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Akebia Therapeutics Inc.

Akebia Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Akebia Therapeutics Inc. The current atr is 0.0543397.

Akebia Therapeutics Inc Daily Average True Range (ATR) ChartAkebia Therapeutics Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Akebia Therapeutics Inc. The current obv is 5,320.

Akebia Therapeutics Inc Daily On-Balance Volume (OBV) ChartAkebia Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Akebia Therapeutics Inc. The current mfi is 0.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Akebia Therapeutics Inc Daily Money Flow Index (MFI) ChartAkebia Therapeutics Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Akebia Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-10-21BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-10-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-23BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-10-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-29ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-31ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-04STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-06BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-07SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-08WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-11-11SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-12RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-11-15ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-11-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-25WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-11-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-27RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-29STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-12-02BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-03RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-12-09STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-10STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-18STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-19MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-12-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-27CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-06WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-01-07STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-08CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-01-09DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-01-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-01-16STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-01-20STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-21ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-23STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-27RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-31STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-02-06STOCH LONG EXITThe %K line crosses below the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-07CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-10WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-17STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-21STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-25RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-02-26STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-27RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-28STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-06SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-12SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside

6.3. Candlestick Patterns

Akebia Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Akebia Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5044.503
Ma 20Greater thanMa 501.779
Ma 50Greater thanMa 1001.911
Ma 100Greater thanMa 2001.814
OpenGreater thanClose1.766
Total2/5 (40.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Akebia Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Akebia Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Akebia Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Akebia Therapeutics Inc

I send you an email if I find something interesting about Akebia Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Akebia Therapeutics Inc.

Receive notifications about Akebia Therapeutics Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.